Aimmune Therapeutics (AIMT) PT Raised to $44 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts AIMT Hot Sheet
Price: $34.49 --0%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 11 | New: 48
Join SI Premium – FREE
JMP Securities analyst Liisa Bayko raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $44.00 (from $40.00) while maintaining a Market Outperform rating.
You May Also Be Interested In
- argenx SE (ARGX) PT Raised to $861 at Baird
- Thermo Fisher Scientific (TMO) PT Raised to $675 at Bernstein SocGen Group
- Waste Connections Inc. (WCN) PT Raised to $210 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
